Skip to main content
. Author manuscript; available in PMC: 2015 Oct 13.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Apr 10;21(8):1460–1470. doi: 10.1016/j.bbmt.2015.04.009

Figure 6.

Figure 6

Comparisons of event-free survival of patients based on (A) donor, match and relation, HLA. (B) occurrence of grade III and IV acute GVHD, (C) receipt of different alemtuzumab schedules, (D) underlying diagnosis, or (E) age group (oldest age quartile versus the lower 3 quartiles).